NUVL

GSK plc (GSK) Launches Tender Offer to Acquire Nuvalent Inc. for $124 Per Share

Price to book forward of Nuvalent, Inc. – NASDAQ:NUVL

Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal

Nuvalent: 'Hold' On GlaxoSmithKline Acquisition For Selective Tyrosine Kinase Inhibitors

Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL

Nuvalent Stock Hits All-Time High Following GSK's Buyout Offer

Nuvalent, Inc. Stock 12‑Month Price Target Cut to $132.81, Implies 50% Upside

GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout

JM Smucker, Nuvalent, FuelCell Energy And Other Big Stocks Moving Higher On Tuesday

GSK Agrees $10.6 Billion Nuvalent Deal at 40% Premium

Nuvalent Stock Soars on $10.6 Billion GSK Buyout

Nuvalent Stock Jumps 39% on Surprise GSK Cancer-Drug Deal

GSK doubles down on oncology with $10.6bn Nuvalent takeover

GSK acquires Nuvalent for $10.6 billion in oncology push

Nuvalent to Be Acquired by GlaxoSmithKline in $124-Per-Share Tender Offer; Holders of 28% Support